1. Croatia, Zagreb, June 29, 2018 Ljiljana Sović Brkičić
The Pharmaceutical Composition
Technology enables controlled concentration of drug in blood
Croatia, Zagreb, June 29, 2018 Ljiljana Sović Brkičić

2. Company Purpose BLC pharmaceutica d.o.o.
BLC pharmaceutica is a small R&D company
Vision … to be important subject in the R&D
Mission
… to find better solution, to manage idaes to…

3. Problem & Solution

4. Value Proposition Users Benefits Patients better drug treatments
better therapy
better quality of life 
therapeutic – lower side effects
economic – saving money
business – staying on job / working
Health insurances / payers
will ensure better treatments
rationalisation of costs
lower costs 
therapeutic – better healthcare
economic - saving money (long-term)
business – better results
Pharmaceutical company
will produce better products
good business opportunity
higher market share 
added value – higher profit
revenues in billion / blockbusters
The Platform

5. Market Opportunity & Risks
European and global
Blockbusters (past and future) Revenues in billion / PH company
The Platform
Usable to all drugs containing N (nitrogen)

6. Competition Example - novel levodopa (antiparkisonic) Competitors
Duodopa
Existing oral formulations
Novel formulation
Price per year
50,000 Euros or more
1,000 Euros
3, ,000 Euros
Administration
parenteral
oral
oral
Features
unacceptable application
causes side effects
well controlled release
Rating of CR
excellent
bad
very good
Evaluation
Expensive
Very inconvenient
Highly effective
Low cost
Convenient
Ineffective
Price acceptable
Convenient
Very Effective

7. § Business Model Licensing (Model 1 of commercialization)
cooperation with big pharmaceutical company (Big PH)
resources, fast model, revenues - up front fee, royalty
revenues in billion (Big PH), in million (SME)
Production (Model 2 of commercialization)
outsourced production, later own production
higher costs, slower realization, longer exploitation
Next proceedings
completing of package for commercialization / licensing
small trials (known main and additonal substances)

8. Commercialization & Marketing
Licensing (Model 1)… Production (Model 2)…
…to Big PH company
crisis in PH industry
lack of good inventions
need for novel products
Big PH likes „Platforms”
commercialization – 3st year
…outsourced production
finalization of R&D
small trials
need for better therapy
registration of medicines
commercialization – 3rd year

9. Financial Projections
Licensing… Production…
Big PH (Model 1)
will conduct marketing
resource, network
production - blockbusters
EU funds – pilot study
future – Model 3
SME (Model 2)
will conduct marketing
need – patients, wholesales
investment – 1,5M Euros
EU funds - commercialization
future – R&D / novel products

10. ? Who we are? Zdravko Dokuzović, PhD Ljiljana Sović Brkičić
Researcher, inventor, technologist, earlier patents
Ljiljana Sović Brkičić
Researcher, inventor, patent applicant, idea, business strategy
Cvjetko Brkičić
Patent applicant, business experience, investment - 1,000,000 €
Team – 95 years of experience; 9 years on this project; 36,500 hours of work (this project)
BLC pharmaceutica d.o.o.
Croatia, Zagreb, Kralja Zvonimira 82
Ljiljana Sović Brkičić